German Phase News Today

Nimic nu este sigur și totul depinde de modul în care merg discuțiile de coaliție pentru formarea noului Guvern în Germania, informează...

Alman FAZ gazetesi: Türk otomobil endüstrisi güçleniyor 08:3011 Temmuz 2021 Alman FAZ gazetesi: Türk otomobil endüstrisi güçleniyor Alman Frankfurter Allgemeine Zeitung (FAZ), Türk otomobil endüstrisinin yeni tip koronavirüs (Kovid-19) salgınından sonra küresel konumunu güçlendirmeye çalıştığını kaydetti. A+A- Erzurum Güncel- Alman Frankfurter Allgemeine Zeitung (FAZ), Türk otomobil endüstrisinin yeni tip koronavirüs (Kovid-19) salgınından sonra küresel konumunu g...

5% Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) — In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into on...

The UK and South African coronavirus mutations are spreading rapidly, fueling record surges in the two nations. The two strains are more infectious than other variants and have reached many other countries, with researchers and health officials worrying about their potential impact on vaccines. A new study shows that the Pfizer/BioNTech vaccine can neutralize the B.1.1.7 strain from the UK. Researchers from South Africa found that monoclonal...

study that evaluated one of the key mutations (N501Y) in the U.K. strain, which is also shared by the South African strain. That study showed efficient neutralization of the N501Y mutated spike bearing virus by sera of individuals who had received the Pfizer-BioNTech COVID-19 vaccine. The current in-vitro study investigated the full set of UK strain spike mutations. To this aim, a pseudovirus featuring the UK strain spike protein was generated. The pseudovirus recapitulates SARS-CoV-2 virus b...

Pfizer and BioNTech have revealed results of an in vitro study that offers additional data on the capability of sera obtained from people who were immunised with their Covid-19 vaccine, BNT162b2, to neutralise the B.1.1.7 lineage (VOC 202012/01).

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that ... BioNTech SEJanuary 20, 2021 GMT New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vac...

Investegate announcements from BioNTech SE, Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

BioNTech SE: Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture Pfizer Inc.and submitted to a peer-reviewed journal. The B.1.1.7 lineage is a rapidly spreading variant of SARS-CoV-2 initially detected in the United Kingdom that carries a larger than usual number of genetic changes with 10 mutations located in the spike protein. BioNTech and Pfizer have previously pu...

(2) Analysis of 37 participants immunized with BNT162b2 showed a broad immune response with SARS-CoV-2-specific neutralizing antibodies, T H1 type CD4+ T cells, and strong expansion of CD8+ T cells of the early effector memory phenotype All vaccinated participants demonstrated neutralizing antibody as well as T cell responses. T cell responses were directed against multiple regions of the spike protein, including the RBD, suggesting immune recognition of multiple independent epitopes Data conf...